Programs Opioids Clinical Primer Resources Canadian Guideline for Opioids for Chronic Non-Cancer Pain
Canadian Guideline for Opioids for Chronic Non-Cancer Pain

Canadian Guideline for Opioids for Chronic Non-Cancer Pain

Evidence, Guidelines and Recommendations

The Canadian Guideline for Opioid for Chronic Non-Cancer Pain was developed in response to concerns that Canadians are the second highest users per capita of opioids in the world, while the rates of opioid prescribing and opioid-related hospital visits and deaths have been increasing rapidly. The guideline's recommendations for clinical practice have been developed by an international team of clinicians, researchers and patients, led by the Michael G. DeGroote National Pain Centre at McMaster University and funded by Health Canada and the Canadian Institutes of Health Research. The guideline was published by the Canadian Medical Association Journal (CMAJ). The guideline incorporates medical evidence published since the previous national opioid use guideline was made available in 2017. They are recommendations for physicians, but are not regulatory requirements. The guideline does not look at opioid use for acute pain, nor for patients with pain due to cancer or in palliative care, or those under treatment for opioid use disorder or opioid addiction. Provided by Michael G. DeGroote National Pain Centre, McMaster University

Details

Category
Evidence, Guidelines and Recommendations
Format
Web Link
Views
0
Added
Apr 3, 2025
Tags
Psychiatry
Pain
Mental Health
Substance Use Disorders
Family Medicine (Primary Care)
Internal Medicine
Emergency Medicine

Related Resources

Web Link
Health Quality Ontario Standards: Opioid Prescribing for Acute Pain
This quality standard includes: quality statements, patient reference guide, recommendations for adoption and a getting started guide
Web Link
Health Quality Ontario Standards: Opioid Use Disorder (Opioid Addiction)
This quality standard includes: quality statements, patient reference guide, recommendations for adoption and a getting started guide.
PDF Document
Recommendations for the use of slow-release oral morphine as opioid agonist therapy
Bringing together published evidence and both clinical and experiential expertise, these recommendations are intended to guide prescribers in the use of slow-release oral morphine (SROM, brand name Kadian) as opioid agonist therapy (OAT).

Stay up to date

Subscribe

News and updates direct to your inbox.

© 2025 McMaster University & Others | 1280 Main St. W. | Hamilton, Ontario L8S 4L8 | Terms of Use